Challenges of New Target Pathways in NSCLC

Speaker: Martin Reck

M.Reck shares expert knowledge on key signalling pathways in NSCLC and current therapeutic possibilities, bridging to possible future improvements and the need to clearly identify the future directions for research.Video produced by the European Society for Medical Oncology (ESMO)

Discussion Points

  • Which signalling pathways are key in NSCLC?
  • Which axes are not targettable so far?
  • In terms of oncogenic drivers, where do we stand in therapeutic targeting today?
  • What are current drawbacks and possible future improvements in targeted therapies against lung cancer?
  • In your opinion, where should research be directed in the future?